Although F5D is defined as a mild and severe disease in cases with activity >5% and <1%, respectively, factor V activity does not necessarily predict bleeding severity or clinical features, and many patients may present with a mild disease even with factor V activity of <1%. However, F5D therapy depends on the factor V activity level, and is classified as bleeding control and the removal of inhibitors or antibodies of factor V. FFP or platelet transfusion is recommended to control bleeding. In particular, transfusing FFP is recommended to maintain factor V activity at >25% to 30% in cases of bleeding, invasive testing, or surgery. In this case, FFP was not transfused because coronary stenting was performed without knowledge of the degree of factor V activity or the existence of F5D. We recognized F5D due to hemoptysis, epistaxis, and hematochezia after coronary stenting. However, we first planned to reduce or modify the dosage of antithrombotic drugs due to the risk of stent thrombosis. This strategy was based on previous reports in which factor V activity was not related to bleeding severity. Moreover, successful childbirth delivery was possible without an FFP transfusion, and the success rate for bleeding control was low with FFP transfusion. Fortunately, mucosal bleeding in the present case was controlled by adjusting the antithrombotic drug dose. Treatments for the inhibitors or antibodies to factor V are another option and include plasmapheresis, immunosuppressants, steroids, intravenous globulins, and a monoclonal antibody. Such therapies were not used in our case because the inhibitors and autoantibodies for factor V were unknown and such therapies have weak evidence.